Informations générales (source: ClinicalTrials.gov)
Interest in PET/CT Whole-body Dynamic Acquisition at FDG to Differentiate Progression/Pseudo Progression of Metastatic Melanoma Under Immunotherapy (IMMUNOPET2)
Observational
University Hospital, Brest (Voir sur ClinicalTrials)
juin 2020
juin 2026
27 juin 2024
The value of 4D body-to-whole dynamic acquisition in FDG PET / CT to differentiate
progression / pseudo-progression during the first therapeutic assessment (PET1) of
metastatic melanoma treated with immune checkpoint inhibitors (ICI)to predict the
progression of the disease..
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hospital University ff Brest - 29200 - Brest - Finistere - France | Ronan ABGRAL, MD-PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patient old ≥ 18 years
- With metastatic melanoma
- Treated with anti-PD1 : Nivolumab or Pembrolizumab or Combo IPI-Nivo
- Having formulated a non-opposition
- Patient old ≥ 18 years
- With metastatic melanoma
- Treated with anti-PD1 : Nivolumab or Pembrolizumab or Combo IPI-Nivo
- Having formulated a non-opposition
-
- Minor patient < 18 years
- Pregnancy or breastfeeding
- Other type of tumor than metastatic melanoma
- Non-eligibility for the examination
- Refusal of participation